

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Potassium channel KCa2.3 (KCNN3; SK3); transmembrane protein 142A (ORAI1; TMEM142A; CRACM1)	<p>Mouse studies suggest inhibiting the interaction between the SK3 and ORAI1 channels could help prevent cancer metastasis. Mice grafted with SK3-deficient human breast cancer cells showed lower cancer cell migration and bone metastasis than those grafted with nondeficient cells.</p> <p>In cultured breast cancer cells and in mouse xenograft models, the lipid ohmline, which inhibits the localization of SK3 and ORAI1 on lipid rafts, decreased cell migration and bone metastasis compared with vehicle. Next steps include determining whether expression of SK3-ORAI1 complex in tumors correlates with risk of bone metastasis.</p>	Reported compounds and screening method to identify anticancer compounds targeting SK3 patented; available for licensing	<p>Chantôme, A. <i>et al. Cancer Res.</i>; published online June 17, 2013; doi:10.1158/0008-5472.CAN-12-4572</p> <p><b>Contact:</b> Christophe Vandier, University Francois Rabelais, Tours, France e-mail: <a href="mailto:christophe.vandier@univ-tours.fr">christophe.vandier@univ-tours.fr</a></p>
		<p><b>SciBX 6(29); doi:10.1038/scibx.2013.753</b> Published online Aug. 1, 2013</p>		